Form 4: ICU Medical COO Christian Voigtlander Reports Stock Transactions
SEC Form 4
Christian Voigtlander, COO of ICU Medical, reports the acquisition and disposal of common stock, including transactions related to restricted stock units.
Summary
- On March 15, 2024, Christian Voigtlander, the Chief Operating Officer of ICU Medical Inc., reported transactions involving the company's common stock.
- Voigtlander acquired 3,247 shares of common stock through the vesting of restricted stock units (RSUs) at a price of $0.00.
- Concurrently, Voigtlander disposed of 1,780 shares of common stock at a price of $98.08 per share.
- Following these transactions, Voigtlander directly owns 12,539 shares of ICU Medical common stock.
- He also holds 6,496 derivative securities in the form of Restricted Stock Units.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the transactions appear to be routine and related to standard executive compensation practices.
Positives
- The vesting of RSUs indicates a form of compensation and alignment of the executive's interests with the company's performance.
Negatives
- The disposal of 1,780 shares could be interpreted negatively, although it may be related to tax obligations arising from the RSU vesting.
Risks
- Executive stock transactions can sometimes be misinterpreted by the market, leading to short-term price volatility.
Industry Context
Executive stock transactions are a common occurrence in publicly traded companies and are often related to compensation packages. Monitoring these transactions can provide insights into management's perspective on the company's value.
Comparison to Industry Standards
- Executive compensation packages often include a mix of salary, stock options, and restricted stock units.
- The vesting schedules for RSUs typically range from three to five years, with annual or quarterly vesting intervals.
- Disposal of shares acquired through vesting is a common practice to cover tax liabilities.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership, but the overall impact is likely to be minimal.
Key Dates
| Date | Description |
|---|---|
| 03/15/2023 | Date the awards were legally granted but subject to shareholder approval. |
| 05/17/2023 | Date of shareholder approval for the awards. |
| 03/15/2024 | Date of the reported transactions (RSU vesting and stock disposal). |
| 03/15/2026 | Expiration date of the derivative security. |
| 03/18/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.